EUVIMEDEUVIMED entdecken
Crossref

Chinese medicine compound prescription HeQi San ameliorates chronic inflammatory states and modulates gut flora in dehydroepiandrosterone-induced polycystic ovary syndrome mouse model

Juntong Li, Deliang Liu, Hengxia Zhao, Pengxiang Zhang, Fangying Cai, Huilin Li, Shufang Chu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Juntong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Gastrointestinal Microbiome, Drugs, Chinese Herbal, Disease Models, Animal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common and complex endocrine disease in women, with a prevalence of 5% to 18% worldwide. HeQi San (HQS) is a Chinese medicine compound prescription, which has been applied to treat various endocrine and metabolic diseases. OBJECTIVE: The study was intended to investigate the effect of HQS on PCOS, and clarify the potential mechanism via in vivo and in vitro experiments. METHODS: The PCOS mouse model was established by injecting the dehydroepiandrosterone (DHEA) subcutaneously and fading high-fat diet for 3 weeks. After making model, PCOS mice were treated with HQS (8.75 g/kg and 17.5 g/kg, ig.) for 4 weeks. Firstly, we assessed the histopathological changes in ovary tissues and detected the hormone level. Subsequently, the study evaluated the capability of anti-inflammatory and regulating macrophage polarization of HQS in vivo and in vitro. The secretion of inflammation indicators was measured with Elisa kits, and the expression level of phosphorylated nuclear factor kappa-B (P-NFκB) and B-lymphocyte activation antigen B7 (CD80) was measured by immunofluorescence and Western blot. Meanwhile, the apoptosis of ovarian granulosa cells was detected via tunel staining and Western blot. The co-culture model in vitro was utilized to assess the effect between macrophage polarization and human ovarian granulosa cells (KGN cells) apoptosis. Furthermore, 16S rDNA sequencing was utilized to elevate gut microbiota change in PCOS mice. RESULTS: HQS reversed the abnormal hormone increase, ameliorated insulin resistance, and improved histopathological changes of the ovary tissue to exert the therapeutic effect. HQS inhibited the expression of P-NF-κB and decreased the production of interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) to further prohibit the macrophage M1 polarization in ovary tissues and macrophages. The apoptosis-positive cells, Bcl-2 Assaciated X protein (BAX), and cleaved-caspase 3 expression were also decreased in the treatment group. The B-cell lymphoma-2 (Bcl2) expression was enhanced after HQS treatment in vivo. The co-culture experiments also verified that HQS could prevent the apoptosis of KGN cells. Furthermore, HQS mediated the abundance of gut flora. The abundance of bifldobacterium and parasutterella was increased and the abundance of lachnoclostridium was decreased. CONCLUSION: The study verified that HQS has the effect of anti-inflammation and inhibits macrophage M1 polarization. Besides, HQS could mediate the abundance of gut microbiota in mice with PCOS. Thus, this study would provide more reasonable basis of HQS for clinical use. In conclusion, HQS might be a potential candidate for PCOS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeGastrointestinal MicrobiomeDrugs, Chinese HerbalDisease Models, AnimalDehydroepiandrosteroneAnti-Inflammatory AgentsAnimalsFemaleMiceOvaryHumansMacrophagesRAW 264.7 CellsCytokinesApoptosisNF-kappa BDiet, High-FatInflammationMice, Inbred C57BL

Stichwörter der Autor:innen

ApoptosisGut floraHeQi SanMacrophagePolycystic ovary syndrome

Substanzen

Drugs, Chinese HerbalDehydroepiandrosteroneAnti-Inflammatory AgentsCytokinesNF-kappa B

Autor:innen und Institutionen

  • Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China.
  • Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China; Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China; Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Electronic address: sztcmlhl@163.com.
  • Department of Endocrinology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China; Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Electronic address: chushufanggzhtcm@163…

Zitieren

APA

Li, J., Liu, D., Zhao, H., Zhang, P., Cai, F., Li, H., & Chu, S. (2024). Chinese medicine compound prescription HeQi San ameliorates chronic inflammatory states and modulates gut flora in dehydroepiandrosterone-induced polycystic ovary syndrome mouse model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112491

Vancouver

Li J, Liu D, Zhao H, Zhang P, Cai F, Li H, et al. Chinese medicine compound prescription HeQi San ameliorates chronic inflammatory states and modulates gut flora in dehydroepiandrosterone-induced polycystic ovary syndrome mouse model. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112491

BibTeX
@article{Li2024,
  author = {Li, Juntong and Liu, Deliang and Zhao, Hengxia and Zhang, Pengxiang and Cai, Fangying and Li, Huilin and Chu, Shufang},
  title = {Chinese medicine compound prescription HeQi San ameliorates chronic inflammatory states and modulates gut flora in dehydroepiandrosterone-induced polycystic ovary syndrome mouse model},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112491}
}
Kostenlos starten →